$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000143774921007756 Filed on March 31, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.870M	$1.720M	$10.62M
YoY Change	8.72%	36.51%	47.09%
% of Gross Profit
Research & Development	$2.360M	$900.0K	$6.645M
YoY Change	162.22%	5.88%	57.85%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$52.79K
YoY Change	0.0%	0.0%	19.44%
% of Gross Profit
Operating Expenses	$4.230M	$2.620M	$17.27M
YoY Change	61.45%	24.17%	51.0%
Operating Profit			-$17.27M
YoY Change			51.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$3.260M	$0.00	$25.65K
YoY Change		-100.0%	-12.46%
Pretax Income	-$7.480M	-$2.620M	-$17.24M
YoY Change	185.5%	25.96%	51.16%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.480M	-$2.620M	-$17.24M
YoY Change	185.5%	25.96%	51.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$446.6K	-$286.7K	-$2.028M
COMMON SHARES
Basic Shares Outstanding		9.131M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.60M	$12.60M	$12.58M
YoY Change	214.29%	21.15%	21.19%
Cash & Equivalents	$39.55M	$12.58M	$12.58M
Short-Term Investments
Other Short-Term Assets	$657.0K	$26.13K	$1.000M
YoY Change	2414.35%	-15.55%	53.85%
Inventory
Prepaid Expenses	$1.814M	$862.3K
Receivables
Other Receivables
Total Short-Term Assets	$42.77M	$14.32M	$14.32M
YoY Change	198.69%	23.98%	23.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.00K	$34.35K	$80.00K
YoY Change	-38.86%	-36.96%	60.0%
Goodwill
YoY Change
Intangibles	$41.00K	$173.5K
YoY Change	-76.37%	-9.64%
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.22K	$20.00K
YoY Change	-1.27%	0.0%	0.0%
Total Long-Term Assets	$69.00K	$170.6K	$170.0K
YoY Change	-59.55%	-0.29%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$42.77M	$14.32M	$14.32M
Total Long-Term Assets	$69.00K	$170.6K	$170.0K
Total Assets	$42.84M	$14.49M	$14.49M
YoY Change	195.65%	23.63%	23.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.589M	$293.2K	$290.0K
YoY Change	442.0%	-17.03%	-17.14%
Accrued Expenses	$93.00K	$77.89K	$1.020M
YoY Change	19.4%	-56.01%	-8.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.67M	$1.323M	$1.320M
YoY Change	1084.74%	-54.63%	-54.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$10.00K
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$10.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.67M	$1.323M	$1.320M
Total Long-Term Liabilities	$0.00	$0.00	$10.00K
Total Liabilities	$15.67M	$1.334M	$1.330M
YoY Change	1074.87%	-54.25%	-54.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$111.9M	-$94.07M
YoY Change	18.95%	22.44%
Common Stock	$138.4M	$106.6M
YoY Change	29.93%	27.98%
Preferred Stock		$671.0K
YoY Change		-71.79%
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.17M	$13.16M	$13.16M
YoY Change
Total Liabilities & Shareholders Equity	$42.84M	$14.49M	$14.49M
YoY Change	195.65%	23.63%	23.63%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$7.480M	-$2.620M	-$17.24M
YoY Change	185.5%	25.96%	51.16%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$52.79K
YoY Change	0.0%	0.0%	19.44%
Cash From Operating Activities	-$3.430M	-$2.710M	-$9.128M
YoY Change	26.57%	11.07%	1.86%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$7.625K
YoY Change		-100.0%	-93.12%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$7.625K
YoY Change		-100.0%	-93.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	33.88M	0.000	11.34M
YoY Change			-7.76%
NET CHANGE
Cash From Operating Activities	-3.430M	-2.710M	-9.128M
Cash From Investing Activities	0.000	0.000	-7.625K
Cash From Financing Activities	33.88M	0.000	11.34M
Net Change In Cash	30.45M	-2.710M	2.201M
YoY Change	-1223.62%	8.4%	-31.62%
FREE CASH FLOW
Cash From Operating Activities	-$3.430M	-$2.710M	-$9.128M
Capital Expenditures	$0.00	$0.00	$7.625K
Free Cash Flow	-$3.430M	-$2.710M	-$9.136M
YoY Change	26.57%	13.87%	0.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q1	atos	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	2800000
CY2020	atos	Common Stock And Warrants Issued During Period Value New Issues CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues	29675342
CY2020Q4	atos	Common Stock Warrant Lability CommonStockWarrantLability	13003075
CY2019Q4	atos	Common Stock Warrant Lability CommonStockWarrantLability
CY2019	atos	Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation	3151944
CY2020	atos	Allocation Of Proceeds To Warrant Liability AllocationOfProceedsToWarrantLiability	4502799
CY2019	atos	Allocation Of Proceeds To Warrant Liability AllocationOfProceedsToWarrantLiability
CY2020	atos	Change In Stock Based Compensation Liability ChangeInStockBasedCompensationLiability
CY2019	atos	Change In Stock Based Compensation Liability ChangeInStockBasedCompensationLiability	1741919
CY2020	atos	Adjustments To Additional Paid In Capital Allocation Of Common Stock Proceeds To Warrant Liability AdjustmentsToAdditionalPaidInCapitalAllocationOfCommonStockProceedsToWarrantLiability	8196428
CY2020	atos	Adjustments To Additional Paid In Capital Allocation Of Convertible Preferred Stock To Beneficial Conversion Feature And Warrant Liability AdjustmentsToAdditionalPaidInCapitalAllocationOfConvertiblePreferredStockToBeneficialConversionFeatureAndWarrantLiability	-2474080
CY2019Q1	atos	Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation	3151944
CY2020Q4	atos	Consummate A Business Combination Percentage Of Acquired Outstanding Shares ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares	0.5
CY2020Q4	atos	Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower	0.5
CY2020Q4	atos	Deferred Tax Assets Lease Obligation DeferredTaxAssetsLeaseObligation	3791
CY2019Q4	atos	Deferred Tax Assets Lease Obligation DeferredTaxAssetsLeaseObligation	10601
CY2020Q4	atos	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	3791
CY2019Q4	atos	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	10601
CY2020	atos	Effective Income Tax Rate Reconciliation Other Deferred Items EffectiveIncomeTaxRateReconciliationOtherDeferredItems	-350113
CY2019	atos	Effective Income Tax Rate Reconciliation Other Deferred Items EffectiveIncomeTaxRateReconciliationOtherDeferredItems	1069111
CY2020Q2	atos	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	20200
CY2020Q2	atos	Increase Decrease In Operating Lease Right Of Use Asset And Liability IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiability	20200
CY2020	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	-104716
CY2019	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	221558
CY2020	atos	Issuance Of Common Stock And Warrants Issuance Costs IssuanceOfCommonStockAndWarrantsIssuanceCosts	1889658
CY2020	atos	Issuance Of Preferred Stock And Warrants Issuance Costs IssuanceOfPreferredStockAndWarrantsIssuanceCosts	259889
CY2020	atos	Lessee Operating Lease Monthly Rent Payments LesseeOperatingLeaseMonthlyRentPayments	750
CY2019	atos	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
CY2020Q4	atos	Professional Services Current ProfessionalServicesCurrent	128229
CY2020Q4	atos	Number Of Shares Authorized To Issue NumberOfSharesAuthorizedToIssue	185000000
CY2020	atos	Preferred Stock And Warrants Issued During Period Value New Issues PreferredStockAndWarrantsIssuedDuringPeriodValueNewIssues	5165111
CY2020	atos	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	4502799
CY2019	atos	Preferred Stock Deemed Dividend PreferredStockDeemedDividend
CY2020	atos	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	28954440
CY2019	atos	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
CY2020	atos	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	4664947
CY2019Q4	atos	Professional Services Current ProfessionalServicesCurrent	108850
CY2020	atos	Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
CY2019	atos	Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation	3151944
CY2020Q4	atos	Research And Development Current ResearchAndDevelopmentCurrent	1215834
CY2019Q4	atos	Research And Development Current ResearchAndDevelopmentCurrent	507733
CY2020Q4	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	634940
CY2019Q4	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	739656
CY2019Q1	atos	Stock Issued During Period Shares Warrant Exercised StockIssuedDuringPeriodSharesWarrantExercised	2800000
CY2019	atos	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	11336710
CY2020	atos	Stock Repurchased During Period For Stock Option Exercise And Taxes Value StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue	-555522
CY2014Q2	atos	Stockholder Rights Agreement Acquiring Person Additional Percentage Of Ownership StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership	0.02
CY2014Q2	atos	Stockholder Rights Agreement Acquiring Person Percentage Of Ownership StockholderRightsAgreementAcquiringPersonPercentageOfOwnership	0.15
CY2014Q2	atos	Stockholder Rights Agreement Initial Exercise Price Of Each Right StockholderRightsAgreementInitialExercisePriceOfEachRight	15
CY2014Q2	atos	Stockholder Rights Agreement Number Of Preferred Stock Right Distributed For Each Share Of Common Stock StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock	1
CY2014Q2	atos	Stockholder Rights Agreement Share Price StockholderRightsAgreementSharePrice	30
CY2020	atos	Warrant Financing Expense WarrantFinancingExpense	938794
CY2019	atos	Warrant Financing Expense WarrantFinancingExpense
CY2020Q4	atos	Working Capital Deficit WorkingCapitalDeficit	27100000
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001488039
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	120824368
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q2	dei	Entity Public Float EntityPublicFloat	35222195
CY2020	dei	Entity Registrant Name EntityRegistrantName	ATOSSA THERAPEUTICS, INC.
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.18 par value
CY2020	dei	Trading Symbol TradingSymbol	atos
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1588613
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	293171
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	689635
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	646064
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	93367
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	77888
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	102918
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	82536
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	171112
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	170820
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	165000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	151200
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	129887146
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	104912480
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7102118
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3019409
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	474641
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3019409
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7102118
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27600
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30800
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8636343
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4908613
CY2020Q4	us-gaap	Assets Assets	42839453
CY2019Q4	us-gaap	Assets Assets	14489855
CY2020Q4	us-gaap	Assets Current AssetsCurrent	42770175
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39553671
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12581136
CY2019Q4	us-gaap	Assets Current AssetsCurrent	14319266
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12691136
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10490493
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39663671
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26972535
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2200643
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	39345260
CY2019Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	12316429
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11570028
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47548835
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9130984
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47548835
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9130984
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8558778
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1643565
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	541
CY2019Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	735
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	449001
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	508289
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	21881
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	21881
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3791
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10783
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7118178
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4505111
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	34100000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	997
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	35933
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	35872
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	5593
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2407591
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1970789
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10034122
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7048088
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	963665
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	899420
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2332567
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	182
CY2020Q4	us-gaap	Deposit Assets DepositAssets	14218
CY2019Q4	us-gaap	Deposit Assets DepositAssets	14218
CY2020	us-gaap	Depreciation Depreciation	19000
CY2019	us-gaap	Depreciation Depreciation	22000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	46520
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52789
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-31732
CY2019	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-5806
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.97
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.03
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	40100
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	105000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13375
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	68542
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7999000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10620008
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17827952
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17239777
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-99186
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	64245
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-35650
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2986034
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1735319
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3743870
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3620353
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	1081835
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	154036
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	26114
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	661887
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1295442
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-60157
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15479
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	631532
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4812
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-8144
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-27047
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	951558
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	352511
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53500
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	173500
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19400
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1400
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6100
CY2020Q4	us-gaap	Liabilities Liabilities	15671521
CY2019Q4	us-gaap	Liabilities Liabilities	1333850
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42839453
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14489855
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15671521
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1322742
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline;" title="notes"></div>NOTE <div style="display: inline; font-style: italic; font: inherit;">1:</div> NATURE OF OPERATIONS</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:72pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.4pt 0pt 5.2pt; text-align: left; text-indent: 54pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 6, 2020, </div>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc. Atossa Therapeutics, Inc. (the “Company”) was incorporated on <div style="display: inline; font-style: italic; font: inherit;"> April 30, 2009, </div>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company's fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31. </div>The Company is currently focused on development of its pharmaceuticals for the treatment of the novel coronavirus ("COVID-<div style="display: inline; font-style: italic; font: inherit;">19"</div>), breast cancer and other breast conditions.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:14.4pt;margin-top:0pt;text-align:left;text-indent:54pt;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:14.4pt;margin-top:0pt;text-align:left;text-indent:54pt;"><div style="display: inline; font-style: italic;">Impact of the Novel Coronavirus </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:28.8pt;margin-right:14.4pt;margin-top:0pt;text-align:left;text-indent:28.8pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.4pt 0pt 7pt; text-align: left; text-indent: 55.8pt;">The continued spread of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is affecting the United States and global economies and <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the Company's operations and those of <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which the Company relies, including causing possible disruptions in the supply of the Company's Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">H201,</div> AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and the conduct of current and future clinical trials. In addition, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the operations of the U.S. Food and Drug Administration and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic could also directly or indirectly impact the pace of enrollment in the Company's clinical trials for at least the next several months and possibly longer as patients <div style="display: inline; font-style: italic; font: inherit;"> may </div>avoid or <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be able to travel to healthcare facilities and physicians' offices except for a health emergency. Such facilities and offices <div style="display: inline; font-style: italic; font: inherit;"> may </div>also be required to focus limited resources on non-clinical trial activities, including treatment of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> patients, and <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be available, in whole or in part, for clinical trial activities related to the Company's products under development. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is difficult to assess or predict, the impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic on the global financial markets <div style="display: inline; font-style: italic; font: inherit;"> may </div>reduce the Company's ability to access capital, which could negatively impact the Company's short-term and long-term liquidity. The ultimate impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is highly uncertain and subject to change. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company's liquidity, capital resources, operations, financial position and business and those of the <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which we rely. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any delay in drug supply for its ongoing and planned clinical studies, including studies of Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and AT-<div style="display: inline; font-style: italic; font: inherit;">H201.</div> The Company anticipates commencing the MBD Endoxifen trial soon after receiving all necessary regulatory approvals; subject to COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> related restrictions that are in place in Stockholm being lifted which could take several months or longer. The Company will continue to monitor future enrollment in studies for potential restrictions on site visits, mammograms or the impositions of new restrictions on trials as a result of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 45pt;">In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on <div style="display: inline; font-style: italic; font: inherit;"> March 27, 2020.  </div>The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferment of employer side social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.  The CARES Act had <div style="display: inline; font-style: italic; font: inherit;">no</div> material impact on the Company's income tax provision for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December </div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020.</div>  The Company continues to examine the elements of the CARES Act and the impact it <div style="display: inline; font-style: italic; font: inherit;"> may </div>have on its financial position, results of operations and cash flows.</div></div>
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38552184
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11336710
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9367
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7625
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11570282
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9128442
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17827952
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-17239777
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22330751
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17239777
CY2020	us-gaap	Operating Expenses OperatingExpenses	14607392
CY2019	us-gaap	Operating Expenses OperatingExpenses	17265425
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-14607392
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-17265425
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	56800
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	56200
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18053
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39371
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11108
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	54900
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	58800
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18053
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50479
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.113
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y36D
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	657662
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	26130
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17218
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17218
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4748
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12892
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	50801
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25648
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	33279
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4792
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14422
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9367
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7625
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	621
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	671
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	1
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	1
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1813902
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	862344
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	417854
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	222476
CY2020Q4	us-gaap	Prepaid Rent PrepaidRent	4488
CY2019Q4	us-gaap	Prepaid Rent PrepaidRent	4275
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	671
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	621
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11308532
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8496964
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	4947219
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11300000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11336710
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	185600
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	185500
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20632
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34350
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6608392
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6645417
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111898992
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94071040
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	670000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4714429
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.16
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	297250
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	155947
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3140000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4308383
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7067436
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.44
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.74
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7067436
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.74
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.40
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.31
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.79
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y94D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y219D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y219D
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	17739
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	12825
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	225000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4664947
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	541100
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3019409
CY2019	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	7102118
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	27167932
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	13156005
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	8805010
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><div style="display: inline; font-weight: bold;">Use of Estimates:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div>
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3000000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1700000

Files In Submission

Name	View Source	Status
0001437749-21-007756-index-headers.html	Edgar Link	pending
0001437749-21-007756-index.html	Edgar Link	pending
0001437749-21-007756.txt	Edgar Link	pending
0001437749-21-007756-xbrl.zip	Edgar Link	pending
atos-20201231.xml	Edgar Link	completed
atos-20201231.xsd	Edgar Link	pending
atos-20201231_cal.xml	Edgar Link	unprocessable
atos-20201231_def.xml	Edgar Link	unprocessable
atos-20201231_lab.xml	Edgar Link	unprocessable
atos-20201231_pre.xml	Edgar Link	unprocessable
atos20201231_10k.htm	Edgar Link	pending
ex_227538.htm	Edgar Link	pending
ex_227543.htm	Edgar Link	pending
ex_227544.htm	Edgar Link	pending
ex_227545.htm	Edgar Link	pending
ex_227546.htm	Edgar Link	pending
ex_227547.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2020 Q4 Form 10-K Financial Statement

#000143774921007756 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2020 Q4 Form 10-K Financial Statement

#000143774921007756 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos